Virginia · J2357

Injection, Omalizumab, 5 Mg in Virginia

Virginia Medicare Avg
$30.01
1% above national avg
National Medicare Avg
$29.60
All states combined
Billed Charge (VA)
$78.95
What providers submit
Est. Commercial (VA)
$83.14
National avg: $83.49
Est. Cash / Self-Pay (VA)
$50.06
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

360.6K
Services in VA
131
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Virginia

Provider Medicare Services
Brennan, Robert MD $30.17 51.8K
Hey, Jamie M.D. $30.06 12.2K
Giessel, Glenn M.D. $30.04 11.5K
Herlihy, Alice MD $30.22 11.4K
Kuno, Ritsu M.D. $30.27 10.5K
Vinson, Laura MD $30.24 10.4K
Sarna, Pawanjit M.D $30.24 10.3K
Sentz, John DO $30.18 9.9K
Sayball, Kristyn DO $30.02 9.3K
Gill, Sujoy MD $29.98 8.4K
Campbell, Timothy M.D. $30.02 8.1K
Crayton, Heidi MD $30.22 8.0K
Price, Katherine MD $30.19 7.6K
Johri, Shilpa MD $30.32 7.4K
Jones, Drew M.D. $30.15 7.1K
Shield, Stephen M.D. $29.61 6.8K

Virginia Pricing in Context

In Virginia, CPT code J2357 (Injection, Omalizumab, 5 Mg) carries an average Medicare payment of $30.01 — 1% above the national benchmark of $29.60. 131 providers across the state submitted claims for this procedure in 2023, performing 360.6K total services. Individual payments in VA ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Virginia is $78.95, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Virginia sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Drugs (Administered) procedures, the estimated commercial insurance price in Virginia lands near $83.14, with self-pay cash prices typically around $50.06. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Injection, Omalizumab, 5 Mg cost in Virginia?

The average Medicare payment for Injection, Omalizumab, 5 Mg in Virginia is $30.01, which is 1% above the national average of $29.60. Providers in VA typically bill $78.95 for this procedure.

What does Injection, Omalizumab, 5 Mg cost with insurance in Virginia?

With commercial insurance in Virginia, Injection, Omalizumab, 5 Mg costs an estimated $83.14. Without insurance, the estimated cash price is $50.06. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Injection, Omalizumab, 5 Mg in Virginia?

131 providers in Virginia billed Medicare for Injection, Omalizumab, 5 Mg in 2023, performing 360.6K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Injection, Omalizumab, 5 Mg cheaper in Virginia than the national average?

No — Injection, Omalizumab, 5 Mg costs 1% above the national average in Virginia. The state average Medicare payment is $30.01 compared to $29.60 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial